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Abstract The binding profile of Triticum vulgaris (WGA,
wheat germ) agglutinin to 23 O-glycans (GalNAcK1CSer/Thr
containing glycoproteins, GPs) was quantitated by the precipitin
assay and its specific interactions with O-glycans were confirmed
by the precipitin inhibition assay. Of the 28 glycoforms tested,
six complex O-glycans (hog gastric mucins, one human blood
group A active and two precursor cyst GPs) reacted strongly with
WGA and completely precipitated the lectin added. All of the
other human blood group A active O-glycans and human blood
group precursor GPs also reacted well with the lectin and
precipitated over two-thirds of the agglutinin used. They reacted
4^50 times stronger than N-glycans (asialo-fetuin and asialo-
human K1 acid GP). The binding of WGA to O-glycans was
inhibited by either p-NO2-phenyl K,LGlcNAc or GalNAc. From
these results, it is highly possible that cluster (multivalent) effects
through the high density of weak inhibitory determinants on
glycans, such as GalNAcK1CSer/Thr (Tn), GalNAc at the non-
reducing terminal, GlcNAcL1C at the non-reducing end and/or
as an internal residue, play important roles in precipitation, while
the GlcNAcL1C4GlcNAc disaccharide may play a minor role in
the precipitation of mammalian glycan-WGA complexes.
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Key words: Wheat germ agglutinin; O-Glycan;
Lectin binding
1. Introduction
Triticum vulgaris agglutinin (wheat germ, WGA) is one of
the most popular applied lectins that has been frequently used
as an investigative tool in glycobiology for over two decades
[1]. Especially conjugates of WGA have been widely used to
purify glycoproteins and glycopeptides, and to study neuronal
cell adhesion molecules [2]. This agglutinin, which is not spe-
ci¢c for human blood groups, shows a much higher a⁄nity
for GlcNAcL1C4GlcNAc (N,NP-diacetylchitobiose) than for
GlcNAc. The a⁄nity of these chitin oligosaccharides for the
lectin increases with size such that the disaccharide is over 100
times and the trisaccharide several thousand times more
tightly bound to WGA than GlcNAc, while GalL1C4Glc-
NAc (N-acetyllactosamine) is a poor inhibitor [1].
GlcNAcL1C4GlcNAc is the essential structural feature
found at the ends of N-linked chains in the carbohydrate-
protein linkage region of N-glycans. WGA binds to peptido-
glycans, chitin, glycosaminoglycans and glycolipids, and also
interacts with some glycoproteins via sialic acid residues [3].
GalNAcK1CSer/Thr-containing glycoproteins (O-glycans)
are very common glycoconjugates in mammalians and play
many important functions in life processes [4^9]. It was
learned from studies on the binding properties of applied lec-
tins that all O-glycans devoid of GlcNAcL1C4GlcNAc (Fig.
1) precipitate strongly with WGA. Therefore, some other de-
terminants should be involved in precipitation of the WGA-
O-glycan complexes. To demonstrate this, we quantitated the
a⁄nity of WGA toward a panel of GalNAcK1CSer/Thr-
linked glycoproteins by the precipitin assay. Its reactivities
toward N-glycans and colominic acid were also compared.
2. Materials and methods
2.1. Glycoproteins and polysaccharide
The glycoproteins tested were prepared from human ovarian cyst
£uid and hog gastric mucosa [8,10^12]. The blood group active gly-
coproteins from human ovarian cyst £uids were puri¢ed by digestion
with pepsin and precipitation with ethanol; the dried ethanol precip-
itates were extracted with 90% phenol, the insoluble fraction being
named according to its blood group glycoprotein (e.g. cyst Beach-
phenol-OH insoluble). The supernatant was fractionally precipitated
by addition of 50% ethanol in 90% phenol to the indicated concen-
trations. The designation 10 or 20% (ppt) denotes a fraction precipi-
tated from phenol at an ethanol concentration of 10 or 20%; 2U
signi¢es that a second phenol extraction and ethanol precipitation
was carried out (e.g. cyst MSS 10% 2U). A proposed representative
carbohydrate side chain is shown in Fig. 1. The P-1 fraction repre-
sents the non-dialyzable portion of the blood group substances after
mild hydrolysis at pH 1.5^2.0 and 100‡C for 2 h which removed most
of the terminal L-fucopyranosyl groups, as well as some blood group
A and B active oligosaccharide side chains [11^14]. The ¢rst Smith
degradation products of the blood group A active substance (MSS
10% 2U), in which almost all of the sugar residues at the non-reduc-
ing end were removed, were prepared according to Wu et al. [8,10^12].
Rat sublingual glycoprotein was prepared by the method of
Moschera and Pigman [7,15,16]. Ovine and porcine salivary glycopro-
teins were puri¢ed according to the modi¢ed method of Tettamanti
and Pigman [17]. Hog stomach mucin #4, hog A+H (structure I in
Fig. 1) [18], was partially puri¢ed from porcine stomach mucin (type
II, M-2378, Sigma) by centrifugation at 10 000Ug for 3 h and exhaus-
tive dialysis against distilled water (molecular weight cut-o¡,
8.0U103). The non-dialyzable fraction was centrifuged to remove in-
soluble material, and lyophilized. Hog gastric mucin #9 was the prod-
uct of hog gastric mucin #4 after treatment at 80‡C, pH 2.0 for 90
min (same condition as desialylation) and hog mucin #14 was the
non-dialyzable fraction (molecular weight cut-o¡ 8.0U103) of hog
mucin #4, after hydrolysis at 100‡C, pH 1.5 for 2 h (Wcyst glyco-
protein P-1). Fetuin [19] and human K1 acid glycoprotein [20,21] were
purchased from Gibco (Grand Island, NY, USA) and Sigma Chem-
ical Company (St. Louis, MO, USA), respectively. Asialo fetuin and
asialo salivary glycoproteins were prepared by mild acid hydrolysis
with 0.01 N HCl at 80‡C for 90 min, and were dialyzed against water
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to remove small fragments [17,22]. Colominic acid was purchased
from Sigma Chemical Company (St. Louis, MO, USA).
2.2. Sugar inhibitors
GalNAc, p-NO2-phenylLGlcNAc, p-NO2-phenylKGlcNAc and Glc
were purchased from Sigma Chemical Company (St. Louis, MO,
USA).
2.3. Lectins
Wheat germ agglutinin (Triticum vulgaris) was purchased form Sig-
ma Chemical Company (St. Louis, MO).
2.4. Lectinochemical (binding) assays [11,23^25]
Quantitative precipitin and precipitin inhibition assays were per-
formed by a microprecipitin technique [26] using 5.0 Wg of lectin
nitrogen for each determination; total N in the washed precipitates
was estimated by the ninhydrin method [27].
3. Results and discussion
Both the quantitative precipitin assay and the quantitative
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Fig. 1. Proposed representative carbohydrate side chains of O-linked glycoproteins (O-glycans), prepared from pig stomach cell linings (Hog
A+H), and human ovarian cyst £uid (Cyst gp). In hog (A+H) (structure I), the terminal sequences (*) are considered to be blood group A+H
and crypto H antigenic determinants. Structure II represents precursor blood group active glycoproteins, which can also be prepared by Smith
degradation of A, B, H active glycoproteins, puri¢ed from human ovarian cyst £uids [8,11]. The four-branched structure (I^IV) is the internal
portion of the carbohydrate moiety of blood group substances to which the residues responsible for A, B, H, Lea, and Leb activities are at-
tached. Numbers in parentheses indicate the site of attachment for the human blood group A, B, H, Lea, and Leb etc. determinants. They are
attached as follows:
Curve Blood group active glycoprotein puri¢ed
from human ovarian cyst £uid
Human blood group
determinant present
Sugar added Site of determinant addition
to structure II
b MSS 1st Smith Ii
c Beach P-1 None
b Mcdon P-1
c Cyst JS phenol insoluble H LFucK1C2 (5), (7), (9), (11)
c Tighe O cyst phenol insoluble Leb LFucK1C4 (6)
Lex LFucK1C3 (8), (10) and/or (12)
b Cyst MSS, native GalNAcK1C3* (1), (2), (3)
b Cyst MSM A or A1 and as in and/or (4)
b Cyst Mcdon H, and Leb (5), (7), (9) and (12)
c Cyst Beach phenol insoluble GalK1C3 and (1), (2), (3)
B same as H, Leb, Lex and/or (4), (5), (7), (9), (6), (8), (10)
or Ley and or (12)
The sugar shown in bold indicates the possible determinants contributing to precipitation and binding (Table 2). Most of the carbohydrate side
chains of Hog (A+H) or cyst gp are part of its corresponding structures shown above.
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precipitin inhibition assay are established methods that can
provide insight into the speci¢cities and size parameters of
lectin-sugar interaction sites. These assays have been success-
fully used to characterize the combining sites of lectins and
the binding properties of glycans for over two decades [28^
31].
The quantitative precipitation curves of WGA with various
glycoforms, especially mammalian O-glycans with blood
group activity and sialylated O-glycans, are shown in Fig. 2.
Of the 28 glycoforms tested, six O-glycans (hog gastric glyco-
protein in Fig. 2a; cyst 9 (A1) in Fig. 2b; cyst JS 1st Smith
degraded in Fig. 2c; cyst Tighe P-1 in Fig. 2c) which do not
contain GlcNAcL1C4 GlcNAcL1C related oligosaccharides,
reacted strongly with WGA. They completely precipitated the
lectin added with less than 5.5 Wg of glycoprotein required for
50% precipitation of 5.0 Wg WGA nitrogen (Table 1), indicat-
ing that some other precipitating factors should be involved in
the WGA-O-glycan interaction. Structures of these glycopro-
teins, as shown in Fig. 1, contain only several weak WGA
inhibitory determinants such as GlcNAcL1C6Gal,
GlcNAcL1C6GalNAc, GlcNAcL1C3, GalNAcK at the
non-reducing terminal and GalNAcK1CSer/Thr at the reduc-
ing end [32^34]. Therefore, the strong precipitation of this
group of glycans most likely depends on the high density of
these weak determinants and the resulting cluster (multiva-
lent) e¡ects [34^36].
In contrast to the poor reactivity of human blood group B
active glycoprotein (Beach phenol insoluble in Fig. 2c), the
strong reactivity of cyst blood group A1 active glycoproteins
(Fig. 2b) indicates that structural (cluster) features of Gal-
NAcK1C at the reducing and non-reducing ends of the sugar
chains should be potent precipitating agents. The precipitabil-
ity of the Smith degraded or P-1 products derived from other
cyst glycoproteins (Fig. 2b,c) can be attributed to the ability
of the WGA to interact with Tn residues, as well as
GlcNAcL1C residues.
Cyst beach glycoprotein with blood group B activity (Fig.
2c) reacted poorly with WGA and precipitated only 12% of
the lectin, but its mild acid hydrolyzed product had an in-
creased reactivity by 48% (Fig. 2c). This di¡erence in binding
can be assumed to be attributable to the strong shielding e¡ect
of blood group B (GalK1C3) key sugar and/or LFucK1C
determinants. The weakly reactive bovine and porcine sub-
mandibular and rat sublingual glycoproteins showed increased
reactivities by 40% after removal of sialic acid (Fig. 2f), dem-
onstrating the possibility of a masking e¡ect of sialic acid. The
asialo products of the N-glycans ^ fetuin and human K1 acid
glycoprotein as tested by QPA ^ showed a loss of reactivity of
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Fig. 2. Quantitative precipitin curves of wheat germ agglutinin with O-glycans, N-glycans and polysaccharide. Conditions: 5.0 Wg WGA nitro-
gen; Total volume 300 Wl.
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more than 50% (Fig. 2d), indicating that sialic acid in both
fetuin and human K1 acid glycoprotein plays a signi¢cant role
in the binding but the binding is weak. Colominic acid, which
is a poly-2,8-N-acetylneuraminic acid, was inactive (Fig. 2d).
Thus, the e¡ect of sialic acids in the interaction of sialoglyco-
proteins with WGA is variable, i.e. structural features of the
sialic acid con¢guration determine its role in binding (Fig. 2d)
or masking (Fig. 2e,f).
The poor precipitability of WGA by the above two N-gly-
cans after mild acid hydrolysis (Fig. 2 and Table 1) can be
explained by an insu⁄cient number of GlcNAcL1C4GlcNAc
sequences in their carbohydrate moiety to precipitate the lec-
tin.
In order to establish that the O-glycan-lectin interaction
occurs through sugar determinants rather than being non-spe-
ci¢c, four sugar inhibitors (GalNAc, p-NO2-phenyl LGlcNAc,
p-NO2-phenyl KGlcNAc and Glc) were used to inhibit the
lectin-O-linked glycoprotein association. When the inhibition
assay was carried out with 5.0 Wg N of WGA and 10 Wg asialo
BSM or asialo OSM (Table 2), nearly 100% of the precipita-
tion was inhibited by 28.5, 2.7 and 2.3 Wmol of GalNAc, p-
NO2-phenyl LGlcNAc and p-NO2-phenyl KGlcNAc, respec-
tively, but insigni¢cantly with 126 Wmol of Glc. The interac-
tion of the O-glycan, puri¢ed from human ovarian cyst £uid
(MSM 10% ppt) with WGA was signi¢cantly inhibited by p-
NO2-phenyl K,LGlcNAc and GalNAc, but not by Glc.
In summary, we conclude that cluster e¡ects a¡orded
through a high density of many weak determinants, such as
GalNAcK1C at non-reducing ends; GalNAcK1CSer/Thr
(Tn) residues and their resulting structural features; GlcNAcL
linked at the non-reducing end and crypto GlcNAcLC, play
a crucial role in the precipitation of WGA, and that
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Table 1
Comparison of precipitation activities of wheat germ agglutinin (T. vulgaris) with various glycoproteins and polysaccharides
Curve in Fig. 2 Glycoprotein or polysaccharide Maximum precipitatedc (Wg N) GPa or PS giving 50% ppt (Wg)
a Hog gastric mucin #4 5.8 (116%) 4
Hog gastric mucin #9 5.6 (112%) 4
Hog gastric mucin #14 5.9 (118%) 3
b Cyst 9 (A1)b 5.0 (100%) 5.5
Cyst MSS 10% 2U (A)b 4.0 (80%) 7
Cyst MSS 1st Smith degraded 4.0 (80%) 7
Cyst MSM 10% ppt (A1)b 4.0 (80%) 8
Cyst Mcdon (A)b 3.6 (72%) 9
Mcdon P-1 (mild acid hydrolyzed) 3.7 (74%) 6
c Cyst JS phenol insoluble (H)b 3.0 (60%) 21
Cyst JS 1st Smith degraded 5.5 (110%) 2
Cyst Tighe O 2.3 (46%) ^
Tighe P-1 5.5 (110%) 5
Cyst Beach phenol insoluble (B)b 0.6 (12%) ^
Cyst Beach P-1 (mild acid hydrolyzed) 3.0 (60%) 11
d Fetuin (GP) 1.0 (20%) ^
Asialo fetuin 0.5 (10%) ^
Human K1 acid GP 1.1 (22%) ^
Asialo human K1 acid GP 0.2 (4%) ^
Colominic acid 0.1 (2%) ^
e Ovine submandibular GP major (OSM) 2.2 (44%) ^
Asialo OSM 3.2 (64%) 4
f Bovine submandibular GP major (BSM) 0.7 (14%) ^
Asialo BSM 2.9 (58%) 6
Rat sublingual GP major 0.2 (4%) ^
Asialo RSL 2.2 (44%) ^
Porcine submandibular GP (PSM) 0.6 (10%) ^
Asialo PSM 2.8 (56%) 11
aGP, glycoproteins; ppt, precipitate.
bThe symbol in parentheses indicates the human blood group activity.
cThe value in parentheses indicates the % of Wg N precipitated at maximum when the amount of lectin added is expressed as 100% (= 5.0 Wg N), in
which the nitrogen contributed by glycoprotein was small.
Table 2
Inhibition of various glycoprotein-WGA interactions by p-nitrophenyl-K,L-D-GlcNAc, GalNAc and Glc
Glycoprotein tested Amount of Inhibition (%)
glycoprotein
(Wg)
28.5 Wmol D-Gal-
NAc added
2.7 Wmol p-nitrophenyl-
L-D-GlcNAc added
2.3 Wmol p-nitrophenyl-
K-D-GlcNAc added
126 Wmol
D-Glc added
Asialo-BSM major 10 100 99.4 100 8.6
Asialo-OSM 10 100 100 98.8 17.3
Human ovarian cyst glyco-
protein (MSM 10% PPT)
15 37.1 84.2 64.0 0
5.0 Wg N of lectin in the centrifuge tube was mixed with or without (control) 28.5 Wmol GalNAc, 2.7 Wmol p-nitrophenyl-L-D-GlcNAc, 2.25 Wmol p-
nitrophenyl-K-D-GlcNAc or 126 Wmol Glc. After incubation at 37‡C for 30 min, 10 or 15 Wg of glycoprotein was added, and incubated at the same
temperature for 1 h and at 4‡C for 6 days.
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GlcNAcL1C4GlcNAc is not an essential precipitating motif
in mammalian O-glycan-WGA interaction. It is conceivable
that other precipitating factors are also involved.
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